Discovery and Optimization of a Novel Class of Orally Active Nonpeptidic Endothelin-A Receptor Antagonists
- 1 January 1996
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 39 (11) , 2123-2128
- https://doi.org/10.1021/jm960274q
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Receptor Selectivity of Endothelin Antagonists and Prevention of Vasoconstriction and Endothelin-Induced Sudden DeathJournal of Cardiovascular Pharmacology, 1995
- Does endothelin-1 play a role in the pathogenesis of cerebral vasospasm?Stroke, 1994
- The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ETA Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5- isoxazolyl)-1-naphthalenesulfonamideJournal of Medicinal Chemistry, 1994
- Endothelin in Chronic Renal FailureNephron, 1994
- Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonistNature, 1993
- Cyclic pentapeptide endothelin antagonists with high ETA selectivity. Potency- and solubility-enhancing modificationsJournal of Medicinal Chemistry, 1992
- Cloning and functional expression of human cDNA for the ETB endothelin receptorBiochemical and Biophysical Research Communications, 1991
- Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptorNature, 1990
- Cloning and expression of a cDNA encoding an endothelin receptorNature, 1990
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988